Reset filter
Nyckelord
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
    1. 7.1. Anestesi
    1. 7.2. Dermatologi
    1. 7.3. HNO
    1. 7.4. Geriatrik
    1. 7.5. Gynekologi och obstetrik
    1. 7.6. Invärtes medicin
      1. Hematologi
      1. Infektionssjukdomar
      1. Kardiologi och angiologi
      1. Pneumologi
      1. Gastroenterologi
      1. Nefrologi
      1. Endokrinologi och ämnesomsättning
      1. Reumatologi
    1. 7.7. Neurologi
    1. 7.8. Oftalmologi
    1. 7.9. Palliativ medicin
    1. 7.10. Patologi och rättsmedicin
    1. 7.11. Pediatrik
    1. 7.12. Psykiatri och psykosomatik
    1. 7.13. Radiologi
    1. 7.14. Kirurgi
      1. Allmänkirurgi och bukkirurgi
      1. Neurokirurgi
      1. Plastikkirurgi
      1. Hjärt- och thoraxkirurgi
      1. Akutkirurgi och ortopedi
      1. Kärlkirurgi
    1. 7.15. Urologi
    1. 7.16. Odontologi samt mun-, käk och ansiktskirurgi
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

1521 Sökresultat.
Relevans Bedömning Nya först Gamla först

Eligibility Non-Hodgkin Lymphoma NCT00384150

- 2018-07-17 - 1 Formulär, 1 Item-grupp, 13 Dataelement, 1 Språk
Item-grupp: Criteria
Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00384150

Eligibility Lymphoma, Non-Hodgkin NCT00347971

- 2017-04-27 - 1 Formulär, 2 Item-grupper, 12 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00347971

Eligibility Lymphoma, Non-Hodgkin NCT00094848

- 2016-10-15 - 1 Formulär, 1 Item-grupp, 13 Dataelement, 1 Språk
Item-grupp: Criteria
Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL); ODM derived from: https://clinicaltrials.gov/show/NCT00094848

Eligibility Leukemia, Myeloid NCT00611247

- 2017-03-07 - 1 Formulär, 2 Item-grupper, 20 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00611247

Eligibility Indolent Non-Hodgkin Lymphoma NCT01882803

- 2020-04-17 - 1 Formulär, 2 Item-grupper, 14 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO); ODM derived from: https://clinicaltrials.gov/show/NCT01882803

Eligibility Lymphoma, Non-Hodgkin NCT01536561

- 2015-12-29 - 1 Formulär, 2 Item-grupper, 13 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01536561

Eligibility Lymphoma, Non-Hodgkin NCT00367497

- 2016-08-08 - 1 Formulär, 2 Item-grupper, 13 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00367497

Eligibility Lymphoma, Non-Hodgkin NCT00268203

- 2016-01-13 - 1 Formulär, 2 Item-grupper, 16 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00268203

Eligibility Lymphoma, Non-Hodgkin NCT00989664

- 2016-02-21 - 1 Formulär, 2 Item-grupper, 17 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00989664

On-Study - Multiple Myeloma - On-Study Form - 2274325v3.0 - Multiple Myeloma - On-Study Form

- 2015-01-09 - 1 Formulär, 4 Item-grupper, 58 Dataelement, 1 Språk
Item-grupper: CRF Header, Myeloma: Form Administration, Myeloma: Disease Description, Myeloma: Prior Treatment
Multiple Myeloma - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6E1DCBD-670E-54A2-E034-0003BA12F5E7

Eligibility Leukemia, Myeloid NCT00512083

- 2018-01-10 - 1 Formulär, 2 Item-grupper, 9 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00512083

Eligibility Acute Myeloid Leukemia NCT00761722

- 2016-03-01 - 1 Formulär, 2 Item-grupper, 19 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00761722

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial